无心血管疾病人群使用多效药片联合或不联合阿司匹林
TIPS-3试验采用2×2×2析因设计,随机纳入5713例无心血管疾病但INTERHEART风险评分升高者,平均随访4.6年。多效药片(辛伐他汀40mg+阿替洛尔100mg+氢氯噻嗪25mg+雷米普利10mg,每日)单用较安慰剂主要终点HR 0.79(95%CI 0.63-1.00);阿司匹林75mg每日单用较安慰剂HR 0.86(95%CI 0.67-1.10);多效药片联合阿司匹林较双安慰剂HR 0.69(95%CI 0.50-0.97)。多效药片组低血压或头晕发生率更高。
要点
- 多效药片联合阿司匹林较双安慰剂显著降低主要心血管事件:HR 0.69(95%CI 0.50-0.97),适用于INTERHEART风险评分升高的无心血管疾病人群。
- 多效药片单用较安慰剂主要终点HR 0.79(95%CI 0.63-1.00),置信区间上限触及1.00。
- 阿司匹林75mg每日单用较安慰剂主要终点HR 0.86(95%CI 0.67-1.10),差异未达统计学显著。
- 多效药片组低血压或头晕发生率高于对应安慰剂组,需关注血压相关不良反应。
- 多效药片使LDL-C降低约19 mg/dL、收缩压降低约5.8 mmHg(与安慰剂比)。
适用人群与场景
- 无心血管疾病且INTERHEART风险评分升高(中等心血管风险)的成人,随机纳入5713例。
诊断标准与关键阈值
- 原文未提及具体INTERHEART风险评分界值或启动/停止阈值。
处置流程与药物剂量
- 多效药片方案:辛伐他汀40mg、阿替洛尔100mg、氢氯噻嗪25mg、雷米普利10mg,每日口服(原文为研究方案,非通用推荐)。
- 阿司匹林75mg每日口服(原文为研究方案)。
- 维生素D或安慰剂每月一次(原文为析因设计的一部分,非本文重点结论)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:2×2×2析因设计RCT,样本量5713例,平均随访4.6年,人群为无心血管疾病且INTERHEART风险评分升高者。
- 多效药片vs安慰剂主要终点(心血管死亡、心梗、卒中、复苏成功的心脏骤停、心衰或血运重建):126例(4.4%)vs 157例(5.5%),HR 0.79(95%CI 0.63-1.00)。
- 阿司匹林vs安慰剂主要终点(心血管死亡、心梗或卒中):116例(4.1%)vs 134例(4.7%),HR 0.86(95%CI 0.67-1.10)。
- 多效药片+阿司匹林vs双安慰剂主要终点:59例(4.1%)vs 83例(5.8%),HR 0.69(95%CI 0.50-0.97)。
- 多效药片组LDL-C降低约19 mg/dL、收缩压降低约5.8 mmHg(与安慰剂比)。
- 多效药片组低血压或头晕发生率高于对应安慰剂组。
证据类型、等级与局限
- 证据类型:RCT(TIPS-3,ClinicalTrials.gov NCT01646437)。
- 局限:原文未明确提及;设计上为中等风险一级预防人群,结果不能外推至其他风险人群。
对床旁实践的改变
- 对无心血管疾病但INTERHEART风险评分升高的中等风险人群,可考虑多效药片联合阿司匹林以降低心血管事件,但需权衡低血压/头晕风险。
- 多效药片单用和阿司匹林单用的效应置信区间均包含1.00,不能据此单独推荐。
- 原文未提及适用与不适用人群的排除标准细节。
指南或共识出处
- TIPS-3 trial(NCT01646437),发表于N Engl J Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A polypill comprising statins, multiple blood-pressure-lowering drugs, and aspirin has been proposed to reduce the risk of cardiovascular disease.
METHODS: Using a 2-by-2-by-2 factorial design, we randomly assigned participants without cardiovascular disease who had an elevated INTERHEART Risk Score to receive a polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothiazide, and 10 mg of ramipril) or placebo daily, aspirin (75 mg) or placebo daily, and vitamin D or placebo monthly. We report here the outcomes for the polypill alone as compared with matching placebo, for aspirin alone as compared with matching placebo, and for the polypill plus aspirin as compared with double placebo. For the polypill-alone and polypill-plus-aspirin comparisons, the primary outcome was death from cardiovascular causes, myocardial infarction, stroke, resuscitated cardiac arrest, heart failure, or revascularization. For the aspirin comparison, the primary outcome was death from cardiovascular causes, myocardial infarction, or stroke. Safety was also assessed.
RESULTS: A total of 5713 participants underwent randomization, and the mean follow-up was 4.6 years. The low-density lipoprotein cholesterol level was lower by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 mm Hg with the polypill and with combination therapy than with placebo. The primary outcome for the polypill comparison occurred in 126 participants (4.4%) in the polypill group and in 157 (5.5%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.63 to 1.00). The primary outcome for the aspirin comparison occurred in 116 participants (4.1%) in the aspirin group and in 134 (4.7%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.67 to 1.10). The primary outcome for the polypill-plus-aspirin comparison occurred in 59 participants (4.1%) in the combined-treatment group and in 83 (5.8%) in the double-placebo group (hazard ratio, 0.69; 95% CI, 0.50 to 0.97). The incidence of hypotension or dizziness was higher in groups that received the polypill than in their respective placebo groups.
CONCLUSIONS: Combined treatment with a polypill plus aspirin led to a lower incidence of cardiovascular events than did placebo among participants without cardiovascular disease who were at intermediate cardiovascular risk. (Funded by the Wellcome Trust and others; TIPS-3 ClinicalTrials.gov number, NCT01646437.).
参考来源
- Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2020. PMID: 33186492. doi:10.1056/NEJMoa2028220
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。